Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.38 |
| ▸ | DRD3 | P35462 | 16/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255653 | 0.85 | HMGCR (0.37) | KDM4EHSD17B10 | |
| SCHEMBL6294671 | 0.85 | NT5E (0.38) | HSP90AA1HSP90AB1NT5EKDM4EALDH1A1 | |
| SCHEMBL26022486 | 0.81 | HSP90AA1 (0.41) | DRD2DRD3HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL1350091 | 0.80 | LMNA (0.30) | — | |
| SCHEMBL13201505 | 0.78 | HSP90AA1 (0.57) | DRD2DRD3HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL13807455 | 0.76 | KDM4E (0.38) | DRD2DRD3HSP90AA1HSP90AB1NT5E | |
| SCHEMBL601813 | 0.76 | HSP90AA1 (0.37) | DRD2DRD3HSP90AA1HSP90AB1 | |
| SCHEMBL17109751 | 0.76 | GABRB2 (0.38) | HSP90AA1HSP90AB1NT5EKDM4EALDH1A1 | |
| SCHEMBL25530095 | 0.75 | — | — | |
| SCHEMBL3707721 | 0.75 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1NT5EKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906221-B1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RES INST (US) | 2019-05-15 | — | — | EP | disclosed |
| US-9969743-B2 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE | 2017-07-06 | — | — | US | disclosed |
| US-9598387-B2 | Urea and amide derivatives of aminoalkylpiperazines and use thereof | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2906221-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | Southern Research Institute (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014059265-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-1003728-B1 | 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate | ABBOTT GMBH & CO KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2272833-A1 | 2-(3-(4-(2-t-Butyl-6-trifluoromethylpyridin-4-yl)piperazin-1-yl)propylmercapto)pyrimidin-4-ol-fumarate | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| EP-0877744-B1 | SUBSTITUTED AZA- AND DIAZACYCLOHEPTANE AND CYCLOOCTANE COMPOUNDS AND THEIR USE | ABBOTT GMBH & CO KG (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-6486162-B2 | FOR THERAPY OF DISORDER OF THE CENTRAL NERVOUS SYSTEM WHICH RESPONDS TO DOPAMINE D3 LIGANDS SUCH AS SCHIZOPHRENIA, DEPRESSION, NEUROSES AND PSYCHOSES | ABBOTT LABORATORIES | 2002-11-26 | — | — | US | disclosed |
| US-20020143179-A1 | 2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-10-03 | — | — | US | disclosed |
| US-6352981-B1 | TREAT DISORDERS WHICH RESPOND TO DOPAMINE D.SUB.3 LIGANDS SUCH AS SCHISTOSOMIASIS, SCHIZOPHRENIA, DEPRESSION, NEUROSES OR PSYCHOSES | BASF AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010020022-A1 | 2{3-[4-(2-T-BUTYL-6-TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL] PROPYLMERCAPTO} PYRIMIDIN-4-OL-FUMARATE | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-06 | — | — | US | disclosed |
| US-6214822-B1 | PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-10 | — | — | US | disclosed |
| US-6103732-A | ENDOTHELIN RECEPTOR INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS; ACUTE MYOCARDIAL INFARCT, PULMONARY HYPERTENSION, RAYNAUD'S SYNDROME, ATHEROSCLEROSIS; ASTHMA; CARDIOVASCULAR DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-15 | — | — | US | disclosed |
| EP-0877744-A1 | SUBSTITUTED AZA- AND DIAZACYCLOHEPTANE AND CYCLOOCTANE COMPOUNDS AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997025324-A1 | SUBSTITUTED AZA- AND DIAZACYCLOHEPTANE AND CYCLOOCTANE COMPOUNDS AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143179-A1 | 2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate | SLC6A3, DRD2, DRD3 | DRD2 2/4885DRD3 3/4885HSP90AA1 3064/4885 |
| US-20170190711-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | HTR2C, HTR4, HTR2A | DRD2 4/4885DRD3 21/4885HSP90AA1 2706/4885 |
| US-20150232435-A1 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF | DRD2, CHRM2, NPY2R | DRD2 1/4885DRD3 6/4885HSP90AA1 3051/4885 |
| US-20010020022-A1 | 2{3-[4-(2-T-BUTYL-6-TRIFLUOROMETHYLPYRIDIN-4-YL) PIPERAZIN-1-YL] PROPYLMERCAPTO} PYRIMIDIN-4-OL-FUMARATE | SLC6A3, DRD2, DRD3 | DRD2 2/4885DRD3 3/4885HSP90AA1 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.